Analysts Set Immix Biopharma, Inc. (NASDAQ:IMMX) PT at $15.00

Immix Biopharma, Inc. (NASDAQ:IMMX) has received a consensus rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $15.00.

A number of brokerages recently commented on IMMX. Mizuho assumed coverage on Immix Biopharma in a research note on Monday, February 9th. They issued an “outperform” rating and a $14.00 price target for the company. Wall Street Zen raised shares of Immix Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Citizens Jmp began coverage on shares of Immix Biopharma in a research report on Monday. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Velan Capital Investment Management LP bought a new position in shares of Immix Biopharma in the 2nd quarter worth approximately $52,000. Vanguard Group Inc. boosted its position in shares of Immix Biopharma by 4.5% during the third quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock valued at $1,526,000 after purchasing an additional 31,625 shares in the last quarter. Tocqueville Asset Management L.P. grew its stake in Immix Biopharma by 37.4% in the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after purchasing an additional 10,950 shares during the period. Imprint Wealth LLC purchased a new stake in Immix Biopharma in the third quarter worth $141,000. Finally, Citadel Advisors LLC bought a new position in Immix Biopharma in the third quarter worth $188,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Stock Performance

Shares of IMMX stock opened at $10.46 on Monday. The firm has a market cap of $553.96 million, a P/E ratio of -13.58 and a beta of 0.25. Immix Biopharma has a fifty-two week low of $1.34 and a fifty-two week high of $10.71. The business’s 50 day moving average price is $6.68 and its 200-day moving average price is $4.65.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.